Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: EKF Diagnostics' PointMan DNA Enrichment Kits

Premium

EKF Diagnostics said this week that it will launch its PointMan DNA enrichment kits at the American Society for Clinical Oncology meeting later this month in Chicago.

The company is commercializing three kits to enrich mutations in BRAF, KRAS, and EGFR T790M genes associated with melanoma, colorectal, and lung cancers. According to the company, PointMan kits offer highly specific and ultra-sensitive enrichment of mutant genes in a background of wild-type genes that is "unmatched" by existing technologies.

PointMan is a real-time PCR technology that is highly efficient in amplifying a target sequence of interest while suppressing amplification of wild-type sequences. The kits can be used to enrich all mutant sequences within a gene of interest using a single set of reagents, as opposed to requiring a separate reagents set for each mutation.

This will be the first product introduction by EKF since it acquired 360 Genomics and established EKF Molecular Diagnostics in March.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.